Volkan SOLMAZ, Sema INANIR, Oytun ERBAS, Dursun DELİBAS

Antipsychotic Like Effects of Atorvastatin and Melatonin in a Psychosis Model in Rats

Amaç: Son yıllarda yapılan çalışmalarda psikoz gibi dopaminerjik bozukluklarla giden hastalıkların patogenezindeserotonerjik bozukluk ve artmış inflamasyon gibi başkamekanizmaların da olabileceğini öne sürülmüştür ve buyolaklarla etkili antipsikotik özelliği olan yeni ilaçlarıngerekliliği belirtilmiştir. Bu çalışmanın amacı, deneyselolarak oluşturulan, apomorfinle tetiklenmiş psikotik dav- ranışlar üzerine atorvastatin ve melatoninin etkileriniincelemektir.Gereç ve Yöntem: Apomorfinle tetiklenmiş steroyotipimodeli in vivo dopamin agonisti yada dopamin anta- gonistlerinin dopaminerjik aktivitelerini değerlendirmekiçin kullanılan deneysel bir modeldir. Çalışmamıza n=6olacak şekilde 7 grup sıçan alındı. Gruplar 10 mg/kg, 20mg/kg atorvastatin, 10 mg/kg ve 20 mg/kg melatonin,%1lik etanol (1 ml/kg), klorpromazin 1mg/kg ve izoto- nik NaCl 1ml/kg olacak şekilde belirlendi. Tüm sıçanlar15er dakikalık periyotlar süresince gözlenerek apomor- finle tetiklenmiş çiğneme hareketleri ve steryotipi skorlarıdeğerlendirildi. Bulgular: 20 mg/kg atorvastatin ve 20 mg/kg mela- tonin çiğneme hareketi skorlarını izotonik verilen grubagöre belirgin derecede azaltmıştı (p

Atorvastatin ve melatoninin psikoz modeli oluşturulmuş sıçanlar üzerine olan antipsi- kotik benzeri etkilerinin incelenemesi

Objective: In recent years besides dopaminergic imbalanceexhibition of other possible mechanisms like inflammationand serotonergic abnormalities have pointed out the needfor new antipsychotic drugs. In this study our aim wasinvestigating the effects of atorvastatin and melatonin inexperimental psychosis model in rats. Materyal and Methods: Apomorphine-induced stereotypyhas been used as a convenient method for in vivo screeningof dopamine agonists or antagonists, and assessmentof dopaminergic activity. All rats were observed andassessed singly in the Plexiglas cage, 7 (n=6) groups ofrat were administered atorvastatin (10, 20 mg/kg, i.p.),melatonin (10, 20 mg/kg, i.p.), 1% ethanol sham (1 ml/ kg, i.p.) chlorpromazine (1 mg/kg; i.p.) or isotonic NaCl(1 ml/kg, i.p.). After apomorphine administration, therats were immediately placed back into the metal cagesand observed for stereotypic and rearing behaviors for15 minutes. Results: Whereas 20 mg/kg of atorvastatin and 20mg/kg of melatonin decreased rearing behavior scorescompared to saline group significantly (p

PDF

___

1. Pichot P. DSM-III: the 3d edition of the Diagnostic and Statistical Manual of Mental Disorders from the American Psychiatric Association. Rev Neurol (Paris). 1986;142:489-99.
2. Rabe-Jablonska J. A new draft of the mental disorders classification prepared by the American Psychiatric Association: diagnostic and statistical manual of mental disorders-IV, Options Book. Psychiatr Pol. 1993;27:109-19.
3. Suvisaari J, Mantere O. Inflammation theories in psychotic disorders: a critical review. Infect Disord Drug Targets. 2013;13:59-70.
4. de Bartolomeis A, Buonaguro EF, Iasevoli F. Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins. Psychopharmacology (Berl). 2013;225:1-19.
5. Lea AP, McTavish D. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs. 1997;53:828-47.
6. Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinsons disease. Mov Disord. 2007;22:377-81.
7. Wahner AD, Bronstein JM, Bordelon YM, Ritz B. Statin use and the risk of Parkinson disease. Neurology. 2008;70:1418-22.
8. Zhou Q, Liao JK. Pleiotropic effects of statins. - Basic research and clinical perspectives. Circ J. 2010;74:818-26.
9. Wang Q, Ting WL, Yang H, Wong PT. High doses of simvastatin upregulate dopamine D1 and D2 receptor expression in the rat prefrontal cortex: possible involvement of endothelial nitric oxide synthase. Br J Pharmacol. 2005;144:933-9.
10. Muhlhauser U, Zolk O, Rau T, Munzel F, Wieland T, Eschenhagen T. Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma- subunits. FASEB J. 2006;20:785-7.
11. Macchi MM, Bruce JN. Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol. 2004;25:177- 95.
12. Anderson G, Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis. 2012;27:113-9.
13. Ajayi AA, Ukponmwan OE. Possible evidence of angiotensin II and endogenous opioid modulation of novelty-induced rearing in the rat. Afr J Med Med Sci. 1994;23:287-90.
14. Labella FS, Pinsky C, Havlicek V. Morphine derivatives with diminished opiate receptor potency show enhanced central excitatory activity. Brain Res. 1979;174:263-71.
15. Reavill C, Kettle A, Holland V, Riley G, Blackburn TP. Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol. 1999;126:572-4.
16. Dong SM, Kim YG, Heo J, Ji MK, Cho JW, Kwak BS. YKP1447, A Novel Potential Atypical Antipsychotic Agent. Korean J Physiol Pharmacol. 2009;13:71-8.
17. Protais P, Costentin J, Schwartz JC. Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology (Berl). 1976;50:1-6.
18. Chaudhry IB, Husain N, Husain MO, Hallak J, Drake R, Kazmi A, et al. Ondansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trial. Trials. 2013;14:101.
19. Bechter K, Reiber H, Herzog S, Fuchs D, Tumani H, Maxeiner HG. Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J Psychiatr Res. 2010;44:321-30.
20. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta- analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011 70:663-71.
21. Kalonia H, Kumar P, Kumar A. Comparative neuroprotective profile of statins in quinolinic acid induced neurotoxicity in rats. Behav Brain Res. 2011;216:220-8.
22. Kumar A, Sharma N, Gupta A, Kalonia H, Mishra J. Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms. Brain Res. 2012;1471:13-22.
23. Wang Q, Wang PH, McLachlan C, Wong PT. Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. Brain Res. 2005;1045:229-33.
24. Wang Q, Tang XN, Wang L, Yenari MA, Ying W, Goh BC, et al. Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD rats. Neurosci Lett. 2006;408:189-93.
25. Park HJ, Park JK, Kim SK, Cho AR, Kim JW, Yim SV, et al. Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients. J Mol Neurosci. 2011;45:304-8.
26. Vigano D, Lissoni P, Rovelli F, Roselli MG, Malugani F, Gavazzeni C, et al. A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia. Neuro Endocrinol Lett. 2001;22:137-41.
27. Bersani G, Mameli M, Garavini A, Pancheri P, Nordio M. Reduction of night/day difference in melatonin blood levels as a possible disease-related index in schizophrenia. Neuro Endocrinol Lett. 2003;24:181-4.
28. Zisapel N, Nir I, Laudon M. Circadian variations in melatonin- binding sites in discrete areas of the male rat brain. FEBS Lett. 1988;232:172-6.
29. Zisapel N, Egozi Y, Laudon M. Inhibition of dopamine release by melatonin: regional distribution in the rat brain. Brain Res. 1982;246:161-3.
30. Sandyk R, Kay SR. Pineal melatonin in schizophrenia: a review and hypothesis. Schizophr Bull. 1990;16:653-62.
31. Esposito E, Cuzzocrea S. Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol. 2010;8:228-42.
32. Maldonado MD, Reiter RJ, Perez-San-Gregorio MA. Melatonin as a potential therapeutic agent in psychiatric illness. Hum Psychopharmacol. 2009;24:391-400.
33. Wareski P, Vaarmann A, Choubey V, Safiulina D, Liiv J, Kuum M, et al. PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons. J Biol Chem. 2009;284:21379-85.
34. Martin M, Macias M, Leon J, Escames G, Khaldy H, Acuna- Castroviejo D. Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int J Biochem Cell Biol. 2002;34:348-57.